Boston Scientific Launches Third-Generation Platinum Chromium Drug-Elu... (clude among other things statements rega...)

Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent

Date:5/19/2009

clude, among other things, statements regarding clinical trials, regulatory approvals, competitive offerings and product performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to al
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials
2. Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientifics TAXUS(R) Liberte(R) Stent
3. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
4. Clinical Data Reinforce Safety and Efficacy of Boston Scientifics Two Drug- Eluting Stent Platforms
5. New England Journal of Medicine Publishes Results from Boston Scientifics Landmark SYNTAX(TM) Trial
6. Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
7. Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent
8. Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientifics Next-Generation Taxus Liberte Stent
9. Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008
10. Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
11. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)

Post Your Comments:

(Date:6/19/2013)... MUMBAI, India , June 19, ... Book Bureau has recently added DrugPatentWatch ... Databases. ( http://www.bharatbook.com/drugpatentwatch-tour.pdf ) ... DrugPatentWatch provides comprehensive information on pharmaceutical, ... value-added information supports the critical business ...

(Date:6/19/2013)... -- Nektar Therapeutics (Nasdaq: NKTR ) today ... study for NKTR-181, a first-in-class, opioid analgesic molecule ... slow rate of entry is designed to reduce the euphoria ... current opioid analgesics. 1 In the study data being ... in "drug liking" and "feeling high" scores and had highly ...

(Date:6/19/2013)... June 19, 2013 BD Biosciences, a segment of ... a leading global medical technology company, today announced the launch ... latest in its line of high-performance research flow cytometers. ... multicolor analysis with the most compact footprint in its class ... a height of 30" (76.2 cm). Recognizing that space is ...

[0] Drug Patent Watch [0] Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence [0] New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research

... , MINNEAPOLIS, Aug. 11 ProUroCare Medical, Inc. (OTC ... the required three centers in its FDA clinical study of the ... , ProUroCare began the current study with the ... having more than 40 patients enrolled overall. Since beginning, five ...

... Aug. 10 Bionovo, Inc. (Nasdaq: BNVI ) today announced second quarter ... , Company Highlights , , , ... in 27 patients with metastatic breast cancer showed ... evidence of clinical activity, in a heavily pretreated ...

Cached Medicine Technology:ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology 2 ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology 3 Bionovo Announces Second Quarter 2009 Highlights and Financial Results 2 Bionovo Announces Second Quarter 2009 Highlights and Financial Results 3 Bionovo Announces Second Quarter 2009 Highlights and Financial Results 4 Bionovo Announces Second Quarter 2009 Highlights and Financial Results 5 Bionovo Announces Second Quarter 2009 Highlights and Financial Results 6 Bionovo Announces Second Quarter 2009 Highlights and Financial Results 7 Bionovo Announces Second Quarter 2009 Highlights and Financial Results 8

ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology Bionovo Announces Second Quarter 2009 Highlights and Financial Results

(Date:6/19/2013)... Salt Lake City, UT (PRWEB) June 19, 2013 ... wellness companies : , In July 2013, Orriant ... optimize their participation rates, and maintain compliance with ... implemented allowing employees to receive wellness incentives if ... Orriant has announced they have been compliant with ...

(Date:6/19/2013)... (PRWEB) June 19, 2013 As ... cancer continue to mount in courts throughout the U.S., ... Drug Administration (FDA) recently held a meeting to discuss ... as incretin mimetics. According to a June 12th ... from the makers of Januvia and similar drugs, following ...

(Date:6/19/2013)... In what is believed to be the largest follow-up ... hereditary dystonia a movement disorder that can cause ... report good success rates and lasting benefits. , Michele ... at Cedars-Sinai Medical Center,s Department of Neurology, and Ron ... at Beth Israel Deaconess Medical Center in Boston, published ...

(Date:6/19/2013)... disparities between minority and white clients in success ... these disparities vary widely from state to state. ... states there,s something amiss," says Stephan Arndt, Ph.D., ... strong racial and ethnic disparities for people in ... successfully, and those disparities are something we need ...

(Date:6/19/2013)... The Movement Disorders Center ... urologists with specialists in physical therapy, occupational therapy ... and their family members to manage diseases and ... also have the opportunity to participate in the ... disorders can be relentlessly progressive and disabling conditions, ...

Breaking Medicine News(10 mins):Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 2 Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 3 Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2 Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3 Health News:Long-term study reports deep brain stimulation effective for most common hereditary dystonia 2 Health News:States vary widely on success rates for minorities in drug treatment programs 2 Health News:States vary widely on success rates for minorities in drug treatment programs 3 Health News:Abington Memorial Hospital’s Neurosciences Institute Opens Movement Disorders Center 2

[0] New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations [0] Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics [0] Long-term study reports deep brain stimulation effective for most common hereditary dystonia [0] States vary widely on success rates for minorities in drug treatment programs [0] Abington Memorial Hospital’s Neurosciences Institute Opens Movement Disorders Center

... healthcare,provider and supplier organizations with its GHXcellence Awards for,achievements ... Friday, April 18, 2008 during a recognition ceremony in,Chicago ... largest healthcare,forum in the U.S. focused on both the ... theme of this year,s awards was improved utilization of ...

... Once locked in decades of isolation, Albania is seeing new ... demands for better and healthier lives. , People ... Institute of Public Health and Hygiene. They want better, more ... keep pace with those expectations, but there are problems. , ...

... Fla., April 23 LifeSync Corporation, a,wholly ... it has entered,into a non-exclusive sublicense with ... with the digital, wireless communication of,patient vital ... Wireless the right to utilize,LifeSync,s technologies in ...

... The Beryl Companies, the nation,s,leading healthcare call ... of operations. In this role she will oversee ... recruitment and,training of managerial staff. Butterfield brings nearly ... vendor management., "Lindy is a highly regarded ...

... for cancer patients , , WEDNESDAY, April 23 (HealthDay News) ... developing a simple way to measure oxygen levels in ... treatment is best for individual patients. , The ... for patients with cancer instead of treating people the ...

... quarter of ... per share, including net realized investment losses ... cash flow was $1.0 billion, or approximately 1.8 times net ... income, -- Full year 2008 net income is now expected to be in the range of $5.42 -, ...

GHXcellence Awards Honor Healthcare Providers and Suppliers for Achievements in Supply Chain Performance Albania: Rising expectations drive growing health care needs LifeSync Corporation Agrees to Sublicense Patent Portfolio to Triage Wireless New VP of Operations Enhances The Beryl Companies' Leadership Team Scan Detects Oxygen Levels in Tumors WellPoint Reports First Quarter 2008 Results

... dryer is an electrophoresis gel vacuum dryer that ... dries these gels onto cellophane or filter paper ... elements which heat gels from above. The drying ... V unit includes power cord, porous gel support, ...

... a constant voltage power supply, the 105 is ... hilo range switch control the output, which is ... volts. One, two-position switch toggles the bright LED ... The 105 is equipped with an over current ...

... From simple techniques such as submarine electrophoresis ... Step IEF, the Series 90 Programmable Power ... Series 90 Programmable Power Supplies are available ... or 6000V., All models operate in constant ...

MP-250N and 300N is a new style power supply. It is a versatile microprocessor power supply for horizontal or vertical gel electrophoresis. The unit is programmable and offers constant voltage and co...

Medicine Products:

Model 583 Gel Dryer (220-240 V)105 Low Voltage Power Supply High Voltage Programmable Power Supplies Midi Power Supply